Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Annexon, Inc.

Get SEC filing alerts via email and in your feed for Annexon, Inc.

ANNX

Annexon, Inc.

About Annexon, Inc.

Annexon, Inc. is a clinical-stage biopharmaceutical company developing novel complement-targeting therapies for inflammatory diseases. Its proprietary platform focuses on inhibiting C1q to block the classical complement pathway implicated in autoimmune, neurodegenerative, and ophthalmologic disorders. Key programs include treatments for Guillain-Barré Syndrome, geographic atrophy in dry AMD, and autoimmune diseases. Annexon holds global rights to its pipeline, leveraging targeted inhibition to preserve immune function while addressing unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Annexon, Inc.

1
1
Annexon, Inc. Annexon Reports $44.1 Million Net Loss in Q1 2026, Focuses on Clinical Programs

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Annexon, Inc. Annexon Reports $206.7 Million Net Loss for 2025, Driven by Increased Operating Expenses

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Annexon, Inc. Annexon Reports $54.9M Net Loss in Q3 2025, Increases R&D Spending

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Annexon, Inc. Annexon Reports $49.2 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Annexon, Inc. Annexon Reports $54.4 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Annexon, Inc. Annexon Reports $138.2 Million Net Loss for Fiscal Year 2024, Advances Key Product Candidates

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Annexon, Inc. Annexon Reports Financial Results, Net Loss, and Cash Position Update for Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments